A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Phase 3
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 852
- Registration Number
- NCT03895203
- Locations
- 🇩🇪
Pa0010 40026, Ratingen, Germany
🇭🇺Pa0010 40030, Eger, Hungary
🇮🇹Pa0010 40084, Catania, Italy
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Phase 3
Completed
- Conditions
- Moderate to Severe Chronic Plaque PsoriasisChronic Plaque Psoriasis
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 172
- Registration Number
- NCT03766685
- Locations
- 🇺🇸
Dv0002 962, Owensboro, Kentucky, United States
🇨🇦Dv0002 651, Richmond Hill, Canada
🇨🇦Dv0002 670, Windsor, Canada
A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
Phase 3
Terminated
- Conditions
- Drug-Resistant EpilepsyFocal-Onset Seizures
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 232
- Registration Number
- NCT03739840
- Locations
- 🇧🇬
Ep0092 150, Blagoevgrad, Bulgaria
🇭🇷Ep0092 128, Zagreb, Croatia
🇪🇪Ep0092 276, Tallinn, Estonia
A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
Phase 3
Terminated
- Conditions
- Restless Legs Syndrome
- Interventions
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 23
- Registration Number
- NCT03728933
- Locations
- 🇺🇸
Sp1006 101, Culver City, California, United States
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Chronic Plaque PsoriasisModerate to Severe Chronic Plaque Psoriasis
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 1353
- Registration Number
- NCT03598790
- Locations
- 🇺🇸
Ps0014 956, Verona, New Jersey, United States
🇺🇸Ps0014 951, Webster, Texas, United States
🇨🇦Ps0014 659, Calgary, Canada
Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT03559686
CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
- Conditions
- Crohn's Disease
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT03559660
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Chronic Plaque PsoriasisModerate to Severe Chronic Plaque Psoriasis
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 743
- Registration Number
- NCT03536884
- Locations
- 🇩🇪
Ps0015 222, Tuebingen, Germany
🇵🇱Ps0015 355, Bialystok, Poland
🇹🇷Ps0015 763, Gaziantep, Turkey
Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy
- Conditions
- Epilepsy
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT03532516
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Chronic Plaque PsoriasisModerate to Severe Plaque Psoriasis
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 478
- Registration Number
- NCT03412747
- Locations
- 🇺🇸
Ps0008 905, Overland Park, Kansas, United States
🇨🇳Ps0008 755, Taipei, Taiwan
🇭🇺Ps0008 260, Szeged, Hungary
© Copyright 2025. All Rights Reserved by MedPath